SOPHiA GENETICS ($SOPH) Insider Trading & Smart Money Activity
SOPHiA GENETICS SA ($SOPH) has 28 insider trades and 2 analyst ratings on file. In the last 12 months on the open market, no insider bought and 13 insiders sold ($935.01K), net -$935.01K.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 13
- Net insider $ (12 mo)
- -$935.01K
- Congress trades (12 mo)
- 0
- 13F moves on file
- 0
- Analyst ratings on file
- 2
SOPH insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 7 · $129.52K | 0 / 0 | 0 / 0 |
| Q3 2026 | 0 | 2 · $9.96K | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 12 · $795.52K | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All SOPH insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Xu ZhenyuChief Scientific Officer | Sell (Open-market sale) 10b5-1 | 4K sh | $28.73K | Read | ||||||
| Insider | Menu PhilippeChief Medical Officer | Sell (Open-market sale) 10b5-1 | 5K sh | $36.30K | Read | ||||||
| Insider | Camblong JurgiExecutive Chairman | Sell (Open-market sale) 10b5-1 | 8.50K sh | $61.67K | Read | ||||||
| Insider | Xu ZhenyuChief Scientific Officer | Sell (Open-market sale) 10b5-1 | 7.39K sh | $60.07K | -12.0% | — | |||||
| Insider | Verma AbhimanyuChief Technology Officer | Sell (Open-market sale) 10b5-1 | 5.28K sh | $42.93K | -12.0% | — | |||||
| Insider | Van Well DaanChief Legal Officer | Sell (Open-market sale) 10b5-1 | 6.17K sh | $50.10K | -12.0% | — | |||||
| Insider | Valente ManuelaChief People Officer | Sell (Open-market sale) 10b5-1 | 4.24K sh | $34.49K | -12.0% | — | |||||
| Insider | Puylaert KevinChief Sales Officer | Sell (Open-market sale) | 216 sh | $1.74K | -12.0% | — | |||||
| Insider | Muken RossChief Executive Officer | Sell (Open-market sale) 10b5-1 | 9.84K sh | $79.97K | -12.0% | — | |||||
| Insider | Menu PhilippeChief Medical Officer | Sell (Open-market sale) 10b5-1 | 7.39K sh | $60.10K | -12.0% | — | |||||
| Insider | George CardozaChief Financial Officer | Sell (Open-market sale) 10b5-1 | 1.59K sh | $12.90K | -12.0% | — | |||||
| Insider | Camblong JurgiExecutive Chairman | Sell (Open-market sale) 10b5-1 | 40.17K sh | $326.53K | -12.0% | — | |||||
| Insider | Muken RossChief Executive Officer | Sell (Open-market sale) 10b5-1 | 422 sh | $3.52K | +3.0% | — | |||||
| Insider | George CardozaChief Financial Officer | Sell (Open-market sale) 10b5-1 | 774 sh | $6.45K | +3.0% | — | |||||
| Insider | Jurgi CamblongChief Executive Officer | Sell (Option exercise) | 31.94K sh | -7.1% | -1.7% | Read | |||||
| Insider | Jurgi CamblongChief Executive Officer | Buy (Option exercise) | 31.94K sh | $100.93K | -7.1% | -1.7% | Read | ||||
| Insider | Abhimanyu VermaChief Technology Officer | Sell (Open-market sale) 10b5-1 | 6.94K sh | $38.26K | -6.0% | -0.7% | Read | ||||
| Insider | Philippe MenuChief Medical Officer | Sell (Open-market sale) 10b5-1 | 5K sh | $27.50K | -6.0% | -0.7% | Read | ||||
| Insider | Jurgi CamblongChief Executive Officer | Sell (Open-market sale) 10b5-1 | 1.37K sh | $7.83K | -6.0% | -0.7% | Read | ||||
| Insider | Ross MukenPresident | Sell (Open-market sale) 10b5-1 | 422 sh | $2.27K | +12.0% | +19.9% | — | ||||
| Insider | George CardozaChief Financial Officer | Sell (Open-market sale) 10b5-1 | 774 sh | $4.16K | +12.0% | +19.9% | — | ||||
| Insider | Vincent Ossipow | Buy (Grant or award) | 19.72K sh | $107.69K | +4.2% | +15.9% | — | ||||
| Insider | Didier Hirsch | Buy (Grant or award) | 28.82K sh | $157.35K | +4.2% | +15.9% | — | ||||
| Insider | Kathy Hibbs | Buy (Grant or award) | 19.72K sh | $107.69K | +4.2% | +15.9% | — | ||||
| Insider | Troy Cox | Buy (Grant or award) | 19.72K sh | $107.69K | +4.2% | +15.9% | — | ||||
| Insider | Jean-Michel Cossery | Buy (Grant or award) | 28.82K sh | $157.35K | +4.2% | +15.9% | — | ||||
| Analyst | BTIG | Reiterates to buy | PT $8 | +6.6% | +15.2% | Read | |||||
| Analyst | BTIG | Reiterates to buy | PT $8 | +6.6% | +15.2% | Read | |||||
| Insider | Philippe MenuChief Medical Officer | Sell (Open-market sale) 10b5-1 | 5K sh | $24.75K | +9.4% | +17.2% | Read | ||||
| Insider | Philippe MenuChief Medical Officer | Sell (Open-market sale) 10b5-1 | 5K sh | $24.75K | +9.4% | +17.2% | — |
1W / 1M / 6M = how SOPH moved from the trade or filing date.
Insider trading in SOPH: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Xu Zhenyu | Chief Scientific Officer | 2 | -$88.80K | Oct 13, 2026 | |
| Menu Philippe | Chief Medical Officer | 2 | -$96.40K | Oct 12, 2026 | |
| Camblong Jurgi | Executive Chairman | 2 | -$388.20K | Oct 12, 2026 | |
| George Cardoza | Chief Financial Officer | 3 | -$23.51K | Oct 5, 2026 | |
| Muken Ross | Chief Executive Officer | 2 | -$83.49K | Oct 5, 2026 | |
| Verma Abhimanyu | Chief Technology Officer | 1 | -$42.93K | Oct 5, 2026 | |
| Van Well Daan | Chief Legal Officer | 1 | -$50.10K | Oct 5, 2026 | |
| Valente Manuela | Chief People Officer | 1 | -$34.49K | Oct 5, 2026 | |
| Puylaert Kevin | Chief Sales Officer | 1 | -$1.74K | Oct 5, 2026 | |
| Jurgi Camblong | Chief Executive Officer | 3 | -$7.83K | Jun 26, 2026 | |
| Philippe Menu | Chief Medical Officer | 3 | -$77K | Jun 25, 2026 | |
| Abhimanyu Verma | Chief Technology Officer | 1 | -$38.26K | Jun 25, 2026 | |
| Ross Muken | President | 1 | -$2.27K | Jun 22, 2026 | |
| Vincent Ossipow | 1 | — | Jun 18, 2026 | ||
| Didier Hirsch | 1 | — | Jun 18, 2026 | ||
| Kathy Hibbs | 1 | — | Jun 18, 2026 | ||
| Troy Cox | 1 | — | Jun 18, 2026 | ||
| Jean-Michel Cossery | 1 | — | Jun 18, 2026 |
Analyst ratings on SOPH
Frequently asked questions
Are SOPH insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 13 insiders made 21 open-market sales worth $935.01K, a net -$935.01K.
What is the latest insider trade in SOPH?
Xu Zhenyu, Chief Scientific Officer filed a sell (open-market sale) of 4K sh worth $28.73K on Oct 13, 2026.
Other health information services stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.